Table 2.

Univariate and multivariate cox proportional hazards regression analysis for recurrence free survival

	RFS
	Univariate analysis			Multivariate analysis
	HR	95% CI	p value	HR	95% CI	p value
Age (≥ 66 vs. < 66)	1.489	0.620–3.576	0.373
Gender (Male vs. female)	0.559	0.235–1.331	0.189
Tumor size at diagnosis (> 2 cm vs. ≤ 2 cm)	0.835	0.322–2.170	0.712
NAT (yes vs. no)	0.952	0.400–2.269	0.912
Radiation (yes vs no)	0.365	0.048–2.755	0.329
CA 19-9 (> 37 U/ml vs. ≤ 37 U/ml)	1.780	0.717–4.417	0.214
DUPAN-2 (> 150 U/ml vs. ≤ 150 U/ml)	2.201	0.931–5.204	0.073
Pathological surgical margin (positive vs. negative)	0.762	0.295–1.969	0.575
Pathological surgical margin (≤ 1 mm vs. > 1 mm)	0.686	0.287–1.641	0.397
Molecular surgical margin (positive vs. negative)	3.989	1.569–10.14	0.004	3.522	1.352–9.179	0.010
CY (positive vs. negative)	0.767	0.177–3.320	0.722
n (positive vs. negative)	0.275	0.037–2.048	0.207
ly (positive vs. negative)	2.706	0.986–7.425	0.053
v (positive vs. negative)	2.841	1.178–6.848	0.020	2.323	0.936–5.769	0.069
s (positive vs. negative)	1.672	0.558–5.012	0.359
rp (positive vs. negative)	1.876	0.630–5.590	0.259
ch (positive vs. negative)	1.735	0.718–4.196	0.221
du (positive vs. negative)	1.249	0.525–2.972	0.615
pv (positive vs. negative)	0.876	0.351–2.188	0.777

Bold indicates P < 0.05

NAT; neoadjuvant chemotherapy, CY; Peritoneal washing cytology, n; Lymph node metastasis, ly; Lymphatic invasion, v; Venous invasion, s; Serosal side of the anterior pancreatic invasion, rp; Retropancreatic tissue invasion, ch; Bile duct invasion, du; Duodenal invasion, pv; Portal vein system invasion